Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials

INTRODUCTION: The efficacy and safety of telavancin versus vancomycin in microbiologically evaluable patients with hospital-acquired or ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus with vancomycin minimum inhibitory concentration (MIC) ≥ 1.0 µg/mL was analyzed using data...

Descripción completa

Detalles Bibliográficos
Autores principales: Niederman, Michael S., Lee, Patrick C., Barriere, Steven L., Barnes, Chris N., Castaneda-Ruiz, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702499/
https://www.ncbi.nlm.nih.gov/pubmed/31372837
http://dx.doi.org/10.1007/s40121-019-0255-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702499/
https://www.ncbi.nlm.nih.gov/pubmed/31372837
http://dx.doi.org/10.1007/s40121-019-0255-0

Ejemplares similares